CONCERT PHARMACEUTICALS, INC.

Inactive Instrument

Analyst Reco. Concert Pharmaceuticals, Inc.

Equities

CNCE

US2060221056

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JMP Securities Downgrades Concert Pharmaceuticals to Market Perform From Market Outperform	23-01-20	MT
Truist Downgrades Concert Pharmaceuticals to Hold Rating From Buy, Adjusts Price Target to $9 From $25	23-01-20	MT
Jefferies Downgrades Concert Pharmaceuticals to Hold From Buy, Adjusts Price Target to $9 From $15	23-01-20	MT
JonesTrading Downgrades Concert Pharmaceuticals to Hold From Buy	23-01-20	MT
Indian shares set for muted start on rate hike concerns	23-01-19	RE
Truist Securities Increases Price Target on Concert Pharmaceuticals to $25 From $22, Maintains Buy Rating	22-09-13	MT
JonesTrading Starts Concert Pharmaceuticals at Buy With $17 Price Target	22-08-25	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	22-07-01	MT
JMP Securities Adjusts Price Target on Concert Pharmaceuticals to $10 From $17, Maintains Market Outperform Rating	21-11-12	MT
Berenberg US CEO Virtual Conference	21-11-08	FA
CONCERT PHARMACEUTICALS : Mizuho Adjusts Price Target on Concert Pharmaceuticals to $9 From $13, Maintains Buy Rating	21-10-05	MT
Berenberg US Conference	21-05-17	FA
CONCERT PHARMACEUTICALS : Truist Securities Adjusts Price Target on Concert Pharmaceuticals to $22 From $30, Maintains Buy Rating	21-02-02	MT
CONCERT PHARMACEUTICALS : HC Wainwright Adjusts Concert Pharmaceuticals' Price Target to $17 from $25, Keeps Buy Rating	21-02-02	MT
CONCERT PHARMACEUTICALS : Berenberg Starts Concert Pharmaceuticals at Buy With $25 Price Target	20-12-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer